Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06275919
Title Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (MIRAGE)
Acronym MIRAGE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Istituto Oncologico Veneto IRCCS
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA


No variant requirements are available.